Why AXT (AXTI) Is Up 21.5% After Boosting Share Authorization And Indium Phosphide Capacity Plans – And What's Next

• In late March 2026, AXT, Inc. proposed amending its Restated Certificate of Incorporation to lift authorized common shares from 70,000,000 to 120,000,000, while also signaling progress on export permits and plans to double indium phosphide manufacturing capacity to meet AI infrastructure demand.
• At the same time, insider share sales and ongoing volatility have contrasted with management’s confidence in AI-related indium phosphide demand, raising important questions about how expanded share authorization and capacity growth could affect existing shareholders.
• We’ll now examine how AXT’s plan to double indium phosphide capacity may reshape its investment narrative and risk-reward profile.

Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

AXT Investment Narrative Recap

To own AXT today, you have to believe that indium phosphide demand from AI infrastructure can eventually outweigh the company’s current export permit hurdles and low-margin profile. The proposed increase in authorized shares and plans to double indium phosphide capacity both tie directly into that short term catalyst, but they also sharpen the near term risk around potential dilution for existing shareholders if more equity is ultimately issued.

The most relevant announcement here is AXT’s plan to double its indium phosphide manufacturing capacity in 2026, backed by management’s comments about progress on export permits. That capacity build is central to the AI substrate thesis, yet it sits against a backdrop of ongoing losses, volatile trading, and significant insider selling, which together heighten the importance of how and when any newly authorized shares might be used.

Yet beneath the AI growth story, investors should be aware that ongoing export permit uncertainty could still...

Read the full narrative on AXT (it's free!)

AXT’s narrative projects $117.8 million in revenue and $16.6 million in earnings by 2028.

Uncover how AXT's forecasts yield a $28.25 fair value, a 56% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue near US$318,000,000 and earnings above US$120,000,000 by 2029, which is far more bullish than consensus and assumes export headwinds ease much faster than the risk of prolonged permit constraints implied before this latest capacity and share authorization news, so it is worth weighing how your own expectations compare with these very different views.

Explore 5 other fair value estimates on AXT - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your AXT research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free AXT research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AXT's overall financial health at a glance.

Searching For A Fresh Perspective?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 58 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com